Progyny Inc. (PGNY)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock?
Progyny (PGNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PGNY or CRL: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
PGNY vs. CRL: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027
Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating. Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrated employer markets—position PGNY for sustained double-digit growth and market share gains.
Wall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here's What You Should Know
The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Progyny Sees Utilization Rebound as Early Renewals De-Risk Outlook
Progyny NASDAQ: PGNY CEO Pete Anevski said the company expects member engagement and utilization to rebound following a more pronounced summer seasonal slowdown, while early renewal and new-client commitments have increased management's confidence in its outlook for the remainder of the year.
Progyny Q2 Earnings Call Highlights
Progyny NASDAQ: PGNY reported record quarterly revenue, gross profit and adjusted EBITDA for the second quarter of 2026, while management said early sales commitments and client-retention activity have positioned the company favorably for the 2027 selling season.
Progyny, Inc. (PGNY) Q2 2026 Earnings Call Transcript
Progyny, Inc. (PGNY) Q2 2026 Earnings Call Transcript
Progyny (PGNY) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Progyny (PGNY) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Progyny (PGNY) Q2 Earnings and Revenues Beat Estimates
Progyny (PGNY) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.48 per share a year ago.
Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Progyny, Inc. (PGNY) Hit a 52 Week High, Can the Run Continue?
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
